JP2020505405A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505405A5 JP2020505405A5 JP2019540518A JP2019540518A JP2020505405A5 JP 2020505405 A5 JP2020505405 A5 JP 2020505405A5 JP 2019540518 A JP2019540518 A JP 2019540518A JP 2019540518 A JP2019540518 A JP 2019540518A JP 2020505405 A5 JP2020505405 A5 JP 2020505405A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- salt form
- pharmaceutical composition
- enantiomer
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 38
- 201000010099 disease Diseases 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 208000011580 syndromic disease Diseases 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 150000003839 salts Chemical group 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
- 208000036142 Viral infection Diseases 0.000 claims description 12
- 230000009385 viral infection Effects 0.000 claims description 12
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
- 208000029742 colonic neoplasm Diseases 0.000 claims description 8
- 125000001153 fluoro group Chemical group F* 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 201000001441 melanoma Diseases 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- DNISYQIZVIFCRA-UHFFFAOYSA-N 4-(1-aminoethyl)-2,6-ditert-butylphenol Chemical compound CC(N)C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 DNISYQIZVIFCRA-UHFFFAOYSA-N 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 208000002672 hepatitis B Diseases 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 150000003573 thiols Chemical class 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- -1 hydroxy, methoxy Chemical group 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000000375 suspending agent Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022137667A JP2022180398A (ja) | 2017-01-27 | 2022-08-31 | Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762451301P | 2017-01-27 | 2017-01-27 | |
| US201762451351P | 2017-01-27 | 2017-01-27 | |
| US62/451,351 | 2017-01-27 | ||
| US62/451,301 | 2017-01-27 | ||
| US201762454135P | 2017-02-03 | 2017-02-03 | |
| US62/454,135 | 2017-02-03 | ||
| PCT/IB2018/050498 WO2018138685A2 (en) | 2017-01-27 | 2018-01-26 | Cyclic dinucleotides as sting agonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022137667A Division JP2022180398A (ja) | 2017-01-27 | 2022-08-31 | Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020505405A JP2020505405A (ja) | 2020-02-20 |
| JP2020505405A5 true JP2020505405A5 (cg-RX-API-DMAC7.html) | 2021-03-04 |
| JP7275031B2 JP7275031B2 (ja) | 2023-05-17 |
Family
ID=61187610
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019540518A Active JP7275031B2 (ja) | 2017-01-27 | 2018-01-26 | Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド |
| JP2022137667A Pending JP2022180398A (ja) | 2017-01-27 | 2022-08-31 | Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022137667A Pending JP2022180398A (ja) | 2017-01-27 | 2022-08-31 | Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11492367B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3573718B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7275031B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110234403A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018212788A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2924186T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018138685A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201912074PA (en) | 2016-03-18 | 2020-02-27 | Immune Sensor Llc | Cyclic di-nucleotide compounds and methods of use |
| JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| RU2020112502A (ru) * | 2017-08-30 | 2021-10-01 | Бейцзин Сюаньи Фармасайенсиз Ко., Лтд. | Циклические динуклеотиды в качестве стимулятора модуляторов генов интерферона |
| WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| MX2020004858A (es) | 2017-11-10 | 2020-10-01 | Takeda Pharmaceuticals Co | Compuestos moduladores de sting y metodos de elaboracion y uso. |
| EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| EP3728282B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| US10519187B2 (en) * | 2018-02-13 | 2019-12-31 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| MX2021002764A (es) | 2018-09-12 | 2021-05-12 | Silverback Therapeutics Inc | Composiciones para el tratamiento de enfermedades con conjugados inmunoestimuladores. |
| US11161864B2 (en) | 2018-10-29 | 2021-11-02 | Venenum Biodesign, LLC | Sting agonists |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| US11293061B2 (en) | 2018-12-26 | 2022-04-05 | Illumina Cambridge Limited | Sequencing methods using nucleotides with 3′ AOM blocking group |
| WO2020178768A1 (en) * | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| EP3966222A4 (en) | 2019-05-09 | 2023-10-04 | Aligos Therapeutics, Inc. | MODIFIED CYCLIC DI-NUCLEOSIDE COMPOUNDS AS STING MODULATORS |
| CA3145889A1 (en) | 2019-07-05 | 2021-01-14 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| CA3151322A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
| KR20250133471A (ko) | 2020-02-18 | 2025-09-05 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 화합물 |
| CN112321589B (zh) * | 2020-02-18 | 2022-05-03 | 山东科巢生物制药有限公司 | 一种抗病毒药物瑞德西韦及其中间体的合成方法 |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| WO2021168274A1 (en) | 2020-02-21 | 2021-08-26 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| US20230141284A1 (en) | 2020-04-10 | 2023-05-11 | Ono Pharmaceutical Co., Ltd. | Cancer therapeutic method |
| BR112022026056A2 (pt) | 2020-06-22 | 2023-03-07 | Illumina Cambridge Ltd | Nucleosídeos e nucleotídeos com grupo bloqueador 3? acetal |
| JP2023532304A (ja) | 2020-07-01 | 2023-07-27 | エーアールエス ファーマシューティカルズ オペレーションズ，インク． | 抗ａｓｇｒ１抗体コンジュゲートおよびその使用 |
| EP4192506A1 (en) | 2020-08-07 | 2023-06-14 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| MX2023005381A (es) | 2020-11-09 | 2023-05-23 | Takeda Pharmaceuticals Co | Conjugados de anticuerpo y farmaco. |
| CA3216162A1 (en) | 2021-04-16 | 2022-10-20 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
| WO2023023527A1 (en) | 2021-08-18 | 2023-02-23 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| EP1368458A2 (en) | 2001-02-26 | 2003-12-10 | Pharma Pacific Pty. Ltd. | Interferon-alpha induced gene |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| US20110159023A1 (en) | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
| TWI605828B (zh) | 2008-12-09 | 2017-11-21 | 建南德克公司 | 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途 |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| WO2013179289A1 (en) | 2012-05-31 | 2013-12-05 | Bio-Lab Ltd. | Pyrazolotriazolyl nucleoside analogues and oligonucleotides comprising them |
| SG10201708821RA (en) | 2013-04-29 | 2017-12-28 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
| WO2014179760A1 (en) * | 2013-05-03 | 2014-11-06 | The Regents Of The University Of California | Cyclic di-nucleotide induction of type i interferon |
| US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| JP6400082B2 (ja) | 2013-05-18 | 2018-10-03 | アデュロ バイオテック，インコーポレイテッド | 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を抑制するための組成物および方法 |
| HUE046942T2 (hu) | 2013-05-18 | 2020-04-28 | Aduro Biotech Inc | Készítmények és eljárások "Interferongén-stimulátor"-tól függõ jelátvitel aktiválására |
| EP3071209A4 (en) | 2013-11-19 | 2017-08-16 | The University of Chicago | Use of sting agonist as cancer treatment |
| EP3152217B1 (en) | 2014-06-04 | 2018-08-01 | GlaxoSmithKline Intellectual Property Development Limited | Cyclic di-nucleotides as modulators of sting |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| HK1249109A1 (zh) | 2015-08-13 | 2018-10-26 | Merck Sharp & Dohme Corp. | 作为sting激动剂的环状二核苷酸化合物 |
| EP3368072A4 (en) * | 2015-10-28 | 2019-07-03 | Aduro BioTech, Inc. | COMPOSITIONS AND METHOD FOR ACTIVATING SIGNALING DEPENDENT ON THE STIMULATOR OF THE INTERFERON GENE |
| ES2863225T3 (es) | 2015-12-03 | 2021-10-11 | Glaxosmithkline Ip Dev Ltd | Dinucleótidos cíclicos purinos como moduladores del sting |
| SG10201912074PA (en) * | 2016-03-18 | 2020-02-27 | Immune Sensor Llc | Cyclic di-nucleotide compounds and methods of use |
| WO2017186711A1 (en) * | 2016-04-25 | 2017-11-02 | Invivogen | Novel complexes of immunostimulatory compounds, and uses thereof |
| JOP20170188A1 (ar) * | 2016-11-25 | 2019-01-30 | Janssen Biotech Inc | ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting) |
| JOP20170192A1 (ar) * | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| WO2018119117A1 (en) * | 2016-12-22 | 2018-06-28 | The Regents Of The University Of California | Methods of producing cyclic dinucleotides |
-
2018
- 2018-01-26 EP EP18703858.3A patent/EP3573718B1/en active Active
- 2018-01-26 ES ES18703858T patent/ES2924186T3/es active Active
- 2018-01-26 JP JP2019540518A patent/JP7275031B2/ja active Active
- 2018-01-26 US US16/478,866 patent/US11492367B2/en active Active
- 2018-01-26 AU AU2018212788A patent/AU2018212788A1/en not_active Abandoned
- 2018-01-26 CN CN201880009026.9A patent/CN110234403A/zh active Pending
- 2018-01-26 WO PCT/IB2018/050498 patent/WO2018138685A2/en not_active Ceased
-
2022
- 2022-08-31 JP JP2022137667A patent/JP2022180398A/ja active Pending
- 2022-11-07 US US17/982,218 patent/US20230146410A1/en active Pending